{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:58:25Z","timestamp":1792515505929,"version":"4.5.0"},"reference-count":66,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Cerebral cavernous malformations (CCMs) are vascular lesions with an overall risk of rupture from 2% to 6% per year, which is associated with significant morbidity and mortality. The diagnostic incidence is increasing, so it is of paramount importance to stratify patients based on their risk of rupture. Data in the literature seem to suggest that specific medications, particularly antithrombotic and cardiovascular agents, are associated with a reduced risk of bleeding. However, the effect of the patient coagulative status on the cumulative bleeding risk remains unclear. The aim of this study was to assess the impact of different radiological, clinical, and pharmacological factors on the bleeding risk of CCMs and to assess the predictive power of an already validated scale for general bleeding risk, the HAS-BLED (hypertension, abnormal renal\/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs\/alcohol concomitantly).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHOD<\/jats:title>\n                    <jats:p>This was a multicenter retrospective observational study. The authors collected imaging, clinical status, and therapy data on patients with bleeding and nonbleeding CCMs. Univariate analysis and subsequent multivariate logistic regression were performed between the considered variables and bleeding or nonbleeding status to identify potential independent predictors of bleeding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      The authors collected data on 257 patients (46.7% male, 25.3% with bleeding CCMs). Compared with patients with nonbleeding lesions, those with bleeding CCMs were younger, less frequently had hypertension, and less frequently required antiplatelet drugs and beta-blockers (all p &lt; 0.05). Bleeding lesions, however, had significantly higher median volumes (1050 mm\n                      <jats:sup>3<\/jats:sup>\n                      vs 523 mm\n                      <jats:sup>3<\/jats:sup>\n                      <jats:sub>,<\/jats:sub>\n                      p &lt; 0.001). On multivariate analyses, after adjusting for age, history of hypertension and diabetes, and use of antiplatelet drugs or beta-blockers, lesion volume \u2265 300 mm\n                      <jats:sup>3<\/jats:sup>\n                      was the only significant predictor of bleeding (adjusted OR 3.11, 95% CI 1.09\u20138.86). When the diagnostic accuracy of different volume thresholds was explored, volume \u2265 300 mm\n                      <jats:sup>3<\/jats:sup>\n                      showed a limited sensitivity (36.7%, 95% CI 24.6%\u201350.0%), but a high specificity 78.2% (95% CI 71.3%\u201384.2%), with an area under the curve of 0.57 (95% CI 0.51\u20130.64).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>This study supports previous findings that the CCM volume is the only factor influencing the bleeding risk. Antithrombotic agents and propranolol seem to have a protective role against the bleeding events. A high HAS-BLED score was not associated with an increased bleeding risk. Further studies are needed to confirm these results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3171\/2023.7.focus23355","type":"journal-article","created":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T09:27:35Z","timestamp":1696152455000},"page":"E15","source":"Crossref","is-referenced-by-count":18,"title":["Bleeding risk evaluation in cerebral cavernous malformation, the role of medications, and hemorrhagic factors: a case-control study"],"prefix":"10.3171","volume":"55","author":[{"given":"Alba","family":"Scerrati","sequence":"first","affiliation":[{"name":"Departments of Translational Medicine and"},{"name":"Department of Neurosurgery, University Hospital S. Anna of Ferrara;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Mantovani","sequence":"additional","affiliation":[{"name":"Departments of Translational Medicine and"},{"name":"Department of Neurosurgery, University Hospital S. Anna of Ferrara;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Travaglini","sequence":"additional","affiliation":[{"name":"Departments of Translational Medicine and"},{"name":"Department of Neurosurgery, University Hospital S. Anna of Ferrara;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Bradaschia","sequence":"additional","affiliation":[{"name":"Department of Neuroscience \"Rita Levi Montalcini,\" Neurosurgery Unit, University of Turin; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"De Bonis","sequence":"additional","affiliation":[{"name":"Departments of Translational Medicine and"},{"name":"Department of Neurosurgery, University Hospital S. Anna of Ferrara;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Farneti","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Hospital S. Anna of Ferrara;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele Alessandro","family":"Cavallo","sequence":"additional","affiliation":[{"name":"Departments of Translational Medicine and"},{"name":"Department of Neurosurgery, University Hospital S. Anna of Ferrara;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Dones","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Hospital S. Anna of Ferrara;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elena","family":"Flacco","sequence":"additional","affiliation":[{"name":"Environmental and Preventive Sciences, University of Ferrara;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Auricchio","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Benato","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Albanese","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo Lucio","family":"Sturiale","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"key":"b1","series-title":"Front Neurol","first-page":"1010170","article-title":"Effects of medication intake on the risk of hemorrhage in patients with sporadic cerebral cavernous malformations","volume":"13","author":"Chen B","year":"2023","unstructured":"Chen B, Lahl K, Saban D,  Effects of medication intake on the risk of hemorrhage in patients with sporadic cerebral cavernous malformations. Front Neurol. 2023;13:1010170."},{"issue":"3","key":"b2","series-title":"Neuroradiology","first-page":"503","article-title":"Incidental findings on 3 T neuroimaging: cross-sectional observations from the population-based Rhineland Study","volume":"64","author":"Lohner V","year":"2022","unstructured":"Lohner V, Lu R, Enkirch SJ, St\u00f6cker T, Hattingen E, Breteler MMB. Incidental findings on 3 T neuroimaging: cross-sectional observations from the population-based Rhineland Study. Neuroradiology. 2022;64(3):503\u2013512."},{"key":"b3","series-title":"World Neurosurg","first-page":"e767","article-title":"Predictors of initial presentation with hemorrhage in patients with cavernous malformations","volume":"133","author":"Flemming KD","year":"2020","unstructured":"Flemming KD, Kumar S, Brown RD Jr, Lanzino G. Predictors of initial presentation with hemorrhage in patients with cavernous malformations. World Neurosurg. 2020;133:e767\u2013e773."},{"issue":"4","key":"b4","series-title":"J Neurosurg","first-page":"1079","article-title":"Hemorrhage from cerebral cavernous malformations: a systematic pooled analysis","volume":"126","author":"Gross BA","year":"2017","unstructured":"Gross BA, Du R. Hemorrhage from cerebral cavernous malformations: a systematic pooled analysis. J Neurosurg. 2017;126(4):1079\u20131087."},{"key":"b5","series-title":"World Neurosurg","first-page":"73","article-title":"Solitary sporadic cerebral cavernous malformations: risk factors of first or recurrent symptomatic hemorrhage and associated functional impairment","volume":"91","author":"Dammann P","year":"2016","unstructured":"Dammann P, Jabbarli R, Wittek P,  Solitary sporadic cerebral cavernous malformations: risk factors of first or recurrent symptomatic hemorrhage and associated functional impairment. World Neurosurg. 2016;91:73\u201380."},{"issue":"5-6","key":"b6","series-title":"Cerebrovasc Dis","first-page":"283","article-title":"Rebleeding and outcome in patients with symptomatic brain stem cavernomas","volume":"43","author":"Arauz A","year":"2017","unstructured":"Arauz A, Pati\u00f1o-Rodriguez HM, Chavarria-Medina M, Becerril M, Longo GM, Nathal E. Rebleeding and outcome in patients with symptomatic brain stem cavernomas. Cerebrovasc Dis. 2017;43(5-6):283\u2013289."},{"key":"b7","series-title":"World Neurosurg","first-page":"e557","article-title":"Hemorrhage risk of untreated isolated cerebral cavernous malformations","volume":"131","author":"Kearns KN","year":"2019","unstructured":"Kearns KN, Chen CJ, Yagmurlu K,  Hemorrhage risk of untreated isolated cerebral cavernous malformations. World Neurosurg. 2019;131:e557\u2013e561."},{"issue":"12","key":"b8","series-title":"J Neurol Neurosurg Psychiatry","first-page":"1366","article-title":"A risk factor analysis of prospective symptomatic haemorrhage in adult patients with cerebral cavernous malformation","volume":"85","author":"Jeon JS","year":"2014","unstructured":"Jeon JS, Kim JE, Chung YS,  A risk factor analysis of prospective symptomatic haemorrhage in adult patients with cerebral cavernous malformation. J Neurol Neurosurg Psychiatry. 2014;85(12):1366\u20131370."},{"issue":"1","key":"b9","series-title":"Neurology","first-page":"e89","article-title":"Hemorrhage from cerebral cavernous malformations: the role of associated developmental venous anomalies","volume":"95","author":"Chen B","year":"2020","unstructured":"Chen B, Herten A, Saban D,  Hemorrhage from cerebral cavernous malformations: the role of associated developmental venous anomalies. Neurology. 2020;95(1):e89\u2013e96."},{"issue":"10","key":"b10","series-title":"Lancet Neurol","first-page":"935","article-title":"Long-term antithrombotic therapy and risk of intracranial haemorrhage from cerebral cavernous malformations: a population-based cohort study, systematic review, and meta-analysis","volume":"18","author":"Zuurbier SM","year":"2019","unstructured":"Zuurbier SM, Hickman CR, Tolias CS,  Long-term antithrombotic therapy and risk of intracranial haemorrhage from cerebral cavernous malformations: a population-based cohort study, systematic review, and meta-analysis. Lancet Neurol. 2019;18(10):935\u2013941."},{"key":"b11","series-title":"J Clin Neurosci","first-page":"246","article-title":"Role of aspirin and statin therapy in patients with cerebral cavernous malformations","volume":"78","author":"Gomez-Paz S","year":"2020","unstructured":"Gomez-Paz S, Salem MM, Maragkos GA,  Role of aspirin and statin therapy in patients with cerebral cavernous malformations. J Clin Neurosci. 2020;78:246\u2013251."},{"issue":"2","key":"b12","series-title":"Neurosurg Rev","first-page":"403","article-title":"Could propranolol be beneficial in adult cerebral cavernous malformations?","volume":"42","author":"Apra C","year":"2019","unstructured":"Apra C, Dumot C, Bourdillon P, Pelissou-Guyotat I. Could propranolol be beneficial in adult cerebral cavernous malformations? Neurosurg Rev. 2019;42(2):403\u2013408."},{"issue":"1","key":"b13","series-title":"Trials","first-page":"401","article-title":"Propranolol for familial cerebral cavernous malformation (Treat_CCM): study protocol for a randomized controlled pilot trial","volume":"21","author":"Lanfranconi S","year":"2020","unstructured":"Lanfranconi S, Scola E, Bertani GA,  Propranolol for familial cerebral cavernous malformation (Treat_CCM): study protocol for a randomized controlled pilot trial. Trials. 2020;21(1):401."},{"issue":"8","key":"b14","series-title":"Stroke","first-page":"2521","article-title":"Association between beta-blocker or statin drug use and the risk of hemorrhage from cerebral cavernous malformations","volume":"53","author":"Zuurbier SM","year":"2022","unstructured":"Zuurbier SM, Hickman CR, Rinkel LA, Berg R, Sure U, Al-Shahi Salman R. Association between beta-blocker or statin drug use and the risk of hemorrhage from cerebral cavernous malformations. Stroke. 2022;53(8):2521\u20132527."},{"key":"b15","series-title":"Neurosurgery","article-title":"Bleeding risk of cerebral cavernous malformations in patients on statin and antiplatelet medication: a cohort study","author":"Marques LL","unstructured":"Marques LL, Jaeggi C, Branca M, Raabe A, Bervini D, Goldberg J. Bleeding risk of cerebral cavernous malformations in patients on statin and antiplatelet medication: a cohort study. Neurosurgery. Published online March 31, 2023. doi:10.1227\/neu.0000000000002480"},{"issue":"2","key":"b16","series-title":"J Am Coll Cardiol","first-page":"173","article-title":"Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal\/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs\/Alcohol Concomitantly) score","volume":"57","author":"Lip GYH","year":"2011","unstructured":"Lip GYH, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal\/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs\/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57(2):173\u2013180."},{"issue":"8","key":"b17","series-title":"Stat Med","first-page":"857","article-title":"Two-sided confidence intervals for the single proportion: comparison of seven methods","volume":"17","author":"Newcombe RG","year":"1998","unstructured":"Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17(8):857\u2013872."},{"issue":"5","key":"b18","series-title":"Stroke","first-page":"1294","article-title":"Familial cerebral cavernous malformations","volume":"50","author":"Zafar A","year":"2019","unstructured":"Zafar A, Quadri SA, Farooqui M,  Familial cerebral cavernous malformations. Stroke. 2019;50(5):1294\u20131301."},{"issue":"5","key":"b19","series-title":"Eur J Neurol","first-page":"1346","article-title":"Modifiable vascular risk factors in patients with cerebral and spinal cavernous malformations: a complete 10-year follow-up study","volume":"30","author":"Rauscher S","year":"2023","unstructured":"Rauscher S, Santos AN, Gull HH,  Modifiable vascular risk factors in patients with cerebral and spinal cavernous malformations: a complete 10-year follow-up study. Eur J Neurol. 2023;30(5):1346\u20131351."},{"issue":"1","key":"b20","series-title":"Pediatrics","first-page":"128","article-title":"Initiation and use of propranolol for infantile hemangioma: report of a consensus conference","volume":"131","author":"Drolet BA","year":"2013","unstructured":"Drolet BA, Frommelt PC, Chamlin SL,  Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131(1):128\u2013140."},{"issue":"5","key":"b21","series-title":"J Am Acad Dermatol","first-page":"833","article-title":"Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls","volume":"64","author":"Hermans DJJ","year":"2011","unstructured":"Hermans DJJ, van Beynum IM, Schultze Kool LJ, van de Kerkhof PCM, Wijnen MHWA, van der Vleuten CJM. Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls. J Am Acad Dermatol. 2011;64(5):833\u2013838."},{"issue":"4","key":"b22","series-title":"JAMA","first-page":"413","article-title":"Safety of propranolol therapy for severe infantile hemangioma","volume":"315","author":"Prey S","year":"2016","unstructured":"Prey S, Voisard JJ, Delarue A,  Safety of propranolol therapy for severe infantile hemangioma. JAMA. 2016;315(4):413\u2013415."},{"issue":"8","key":"b23","series-title":"N Engl J Med","first-page":"735","article-title":"A randomized, controlled trial of oral propranolol in infantile hemangioma","volume":"372","author":"L\u00e9aut\u00e9-Labr\u00e8ze C","year":"2015","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, Hoeger P, Mazereeuw-Hautier J,  A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372(8):735\u2013746."},{"key":"b24","series-title":"Placenta","first-page":"93","article-title":"The embryo-placental CD15-positive \"vasculogenic zones\" as a source of propranolol-sensitive pediatric vascular tumors","volume":"38","author":"Seidmann L","year":"2016","unstructured":"Seidmann L, Anspach L, Roth W. The embryo-placental CD15-positive \"vasculogenic zones\" as a source of propranolol-sensitive pediatric vascular tumors. Placenta. 2016;38:93\u201399."},{"issue":"1","key":"b25","series-title":"Lancet Neurol","first-page":"35","article-title":"Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial","volume":"22","author":"Lanfranconi S","year":"2023","unstructured":"Lanfranconi S, Scola E, Meessen JMTA,  Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial. Lancet Neurol. 2023;22(1):35\u201344."},{"issue":"3","key":"b26","series-title":"J Clin Invest","first-page":"e144893","article-title":"Propranolol inhibits cavernous vascular malformations by \u03b21 adrenergic receptor antagonism in animal models","volume":"131","author":"Li W","year":"2021","unstructured":"Li W, Shenkar R, Detter MR,  Propranolol inhibits cavernous vascular malformations by \u03b21 adrenergic receptor antagonism in animal models. J Clin Invest. 2021;131(3):e144893."},{"issue":"12","key":"b27","series-title":"Stroke","first-page":"3196","article-title":"Antithrombotic therapy and bleeding risk in a prospective cohort study of patients with cerebral cavernous malformations","volume":"43","author":"Schneble HM","year":"2012","unstructured":"Schneble HM, Soumare A, Herv\u00e9 D,  Antithrombotic therapy and bleeding risk in a prospective cohort study of patients with cerebral cavernous malformations. Stroke. 2012;43(12):3196\u20133199."},{"issue":"4","key":"b28","series-title":"Arterioscler Thromb Vasc Biol","first-page":"728","article-title":"Platelet adhesion receptors and their ligands in mouse models of thrombosis","volume":"27","author":"Denis CV","year":"2007","unstructured":"Denis CV, Wagner DD. Platelet adhesion receptors and their ligands in mouse models of thrombosis. Arterioscler Thromb Vasc Biol. 2007;27(4):728\u2013739."},{"issue":"4","key":"b29","series-title":"PLoS One","first-page":"e0122520","article-title":"The HAS-BLED score identifies patients with acute venous thromboembolism at high risk of major bleeding complications during the first six months of anticoagulant treatment","volume":"10","author":"Kooiman J","year":"2015","unstructured":"Kooiman J, van Hagen N, Iglesias Del Sol A,  The HAS-BLED score identifies patients with acute venous thromboembolism at high risk of major bleeding complications during the first six months of anticoagulant treatment. PLoS One. 2015;10(4):e0122520."},{"key":"b30","series-title":"Ann Vasc Surg","first-page":"190","article-title":"HAS-BLED score predicts the risk of major bleeding in chronic anticoagulation after lower limb surgical revascularization","volume":"59","author":"Freixo C","year":"2019","unstructured":"Freixo C, Ferreira V, Gon\u00e7alves J,  HAS-BLED score predicts the risk of major bleeding in chronic anticoagulation after lower limb surgical revascularization. Ann Vasc Surg. 2019;59:190\u2013194."},{"issue":"19","key":"b31","series-title":"J Am Heart Assoc","first-page":"e017316","article-title":"Predictors of bleeding in the perioperative anticoagulant use for surgery evaluation study","volume":"9","author":"Tafur AJ","year":"2020","unstructured":"Tafur AJ, Clark NP, Spyropoulos AC,  Predictors of bleeding in the perioperative anticoagulant use for surgery evaluation study. J Am Heart Assoc. 2020;9(19):e017316."},{"issue":"9","key":"b32","series-title":"J Am Coll Cardiol","first-page":"861","article-title":"Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study","volume":"60","author":"Apostolakis S","year":"2012","unstructured":"Apostolakis S, Lane DA, Guo Y, Buller H, Lip GYH. Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol. 2012;60(9):861\u2013867."},{"issue":"12","key":"b33","series-title":"Eur Heart J","first-page":"1500","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study","volume":"33","author":"Friberg L","year":"2012","unstructured":"Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500\u20131510."},{"key":"b1","series-title":"Front Neurol","first-page":"1010170","article-title":"Effects of medication intake on the risk of hemorrhage in patients with sporadic cerebral cavernous malformations","volume":"13","author":"Chen B","year":"2023","unstructured":"Chen B, Lahl K, Saban D,  Effects of medication intake on the risk of hemorrhage in patients with sporadic cerebral cavernous malformations. Front Neurol. 2023;13:1010170."},{"issue":"3","key":"b2","series-title":"Neuroradiology","first-page":"503","article-title":"Incidental findings on 3 T neuroimaging: cross-sectional observations from the population-based Rhineland Study","volume":"64","author":"Lohner V","year":"2022","unstructured":"Lohner V, Lu R, Enkirch SJ, St\u00f6cker T, Hattingen E, Breteler MMB. Incidental findings on 3 T neuroimaging: cross-sectional observations from the population-based Rhineland Study. Neuroradiology. 2022;64(3):503\u2013512."},{"key":"b3","series-title":"World Neurosurg","first-page":"e767","article-title":"Predictors of initial presentation with hemorrhage in patients with cavernous malformations","volume":"133","author":"Flemming KD","year":"2020","unstructured":"Flemming KD, Kumar S, Brown RD Jr, Lanzino G. Predictors of initial presentation with hemorrhage in patients with cavernous malformations. World Neurosurg. 2020;133:e767\u2013e773."},{"issue":"4","key":"b4","series-title":"J Neurosurg","first-page":"1079","article-title":"Hemorrhage from cerebral cavernous malformations: a systematic pooled analysis","volume":"126","author":"Gross BA","year":"2017","unstructured":"Gross BA, Du R. Hemorrhage from cerebral cavernous malformations: a systematic pooled analysis. J Neurosurg. 2017;126(4):1079\u20131087."},{"key":"b5","series-title":"World Neurosurg","first-page":"73","article-title":"Solitary sporadic cerebral cavernous malformations: risk factors of first or recurrent symptomatic hemorrhage and associated functional impairment","volume":"91","author":"Dammann P","year":"2016","unstructured":"Dammann P, Jabbarli R, Wittek P,  Solitary sporadic cerebral cavernous malformations: risk factors of first or recurrent symptomatic hemorrhage and associated functional impairment. World Neurosurg. 2016;91:73\u201380."},{"issue":"5-6","key":"b6","series-title":"Cerebrovasc Dis","first-page":"283","article-title":"Rebleeding and outcome in patients with symptomatic brain stem cavernomas","volume":"43","author":"Arauz A","year":"2017","unstructured":"Arauz A, Pati\u00f1o-Rodriguez HM, Chavarria-Medina M, Becerril M, Longo GM, Nathal E. Rebleeding and outcome in patients with symptomatic brain stem cavernomas. Cerebrovasc Dis. 2017;43(5-6):283\u2013289."},{"key":"b7","series-title":"World Neurosurg","first-page":"e557","article-title":"Hemorrhage risk of untreated isolated cerebral cavernous malformations","volume":"131","author":"Kearns KN","year":"2019","unstructured":"Kearns KN, Chen CJ, Yagmurlu K,  Hemorrhage risk of untreated isolated cerebral cavernous malformations. World Neurosurg. 2019;131:e557\u2013e561."},{"issue":"12","key":"b8","series-title":"J Neurol Neurosurg Psychiatry","first-page":"1366","article-title":"A risk factor analysis of prospective symptomatic haemorrhage in adult patients with cerebral cavernous malformation","volume":"85","author":"Jeon JS","year":"2014","unstructured":"Jeon JS, Kim JE, Chung YS,  A risk factor analysis of prospective symptomatic haemorrhage in adult patients with cerebral cavernous malformation. J Neurol Neurosurg Psychiatry. 2014;85(12):1366\u20131370."},{"issue":"1","key":"b9","series-title":"Neurology","first-page":"e89","article-title":"Hemorrhage from cerebral cavernous malformations: the role of associated developmental venous anomalies","volume":"95","author":"Chen B","year":"2020","unstructured":"Chen B, Herten A, Saban D,  Hemorrhage from cerebral cavernous malformations: the role of associated developmental venous anomalies. Neurology. 2020;95(1):e89\u2013e96."},{"issue":"10","key":"b10","series-title":"Lancet Neurol","first-page":"935","article-title":"Long-term antithrombotic therapy and risk of intracranial haemorrhage from cerebral cavernous malformations: a population-based cohort study, systematic review, and meta-analysis","volume":"18","author":"Zuurbier SM","year":"2019","unstructured":"Zuurbier SM, Hickman CR, Tolias CS,  Long-term antithrombotic therapy and risk of intracranial haemorrhage from cerebral cavernous malformations: a population-based cohort study, systematic review, and meta-analysis. Lancet Neurol. 2019;18(10):935\u2013941."},{"key":"b11","series-title":"J Clin Neurosci","first-page":"246","article-title":"Role of aspirin and statin therapy in patients with cerebral cavernous malformations","volume":"78","author":"Gomez-Paz S","year":"2020","unstructured":"Gomez-Paz S, Salem MM, Maragkos GA,  Role of aspirin and statin therapy in patients with cerebral cavernous malformations. J Clin Neurosci. 2020;78:246\u2013251."},{"issue":"2","key":"b12","series-title":"Neurosurg Rev","first-page":"403","article-title":"Could propranolol be beneficial in adult cerebral cavernous malformations?","volume":"42","author":"Apra C","year":"2019","unstructured":"Apra C, Dumot C, Bourdillon P, Pelissou-Guyotat I. Could propranolol be beneficial in adult cerebral cavernous malformations? Neurosurg Rev. 2019;42(2):403\u2013408."},{"issue":"1","key":"b13","series-title":"Trials","first-page":"401","article-title":"Propranolol for familial cerebral cavernous malformation (Treat_CCM): study protocol for a randomized controlled pilot trial","volume":"21","author":"Lanfranconi S","year":"2020","unstructured":"Lanfranconi S, Scola E, Bertani GA,  Propranolol for familial cerebral cavernous malformation (Treat_CCM): study protocol for a randomized controlled pilot trial. Trials. 2020;21(1):401."},{"issue":"8","key":"b14","series-title":"Stroke","first-page":"2521","article-title":"Association between beta-blocker or statin drug use and the risk of hemorrhage from cerebral cavernous malformations","volume":"53","author":"Zuurbier SM","year":"2022","unstructured":"Zuurbier SM, Hickman CR, Rinkel LA, Berg R, Sure U, Al-Shahi Salman R. Association between beta-blocker or statin drug use and the risk of hemorrhage from cerebral cavernous malformations. Stroke. 2022;53(8):2521\u20132527."},{"key":"b15","series-title":"Neurosurgery","article-title":"Bleeding risk of cerebral cavernous malformations in patients on statin and antiplatelet medication: a cohort study","author":"Marques LL","unstructured":"Marques LL, Jaeggi C, Branca M, Raabe A, Bervini D, Goldberg J. Bleeding risk of cerebral cavernous malformations in patients on statin and antiplatelet medication: a cohort study. Neurosurgery. Published online March 31, 2023. doi:10.1227\/neu.0000000000002480"},{"issue":"2","key":"b16","series-title":"J Am Coll Cardiol","first-page":"173","article-title":"Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal\/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs\/Alcohol Concomitantly) score","volume":"57","author":"Lip GYH","year":"2011","unstructured":"Lip GYH, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal\/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs\/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57(2):173\u2013180."},{"issue":"8","key":"b17","series-title":"Stat Med","first-page":"857","article-title":"Two-sided confidence intervals for the single proportion: comparison of seven methods","volume":"17","author":"Newcombe RG","year":"1998","unstructured":"Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17(8):857\u2013872."},{"issue":"5","key":"b18","series-title":"Stroke","first-page":"1294","article-title":"Familial cerebral cavernous malformations","volume":"50","author":"Zafar A","year":"2019","unstructured":"Zafar A, Quadri SA, Farooqui M,  Familial cerebral cavernous malformations. Stroke. 2019;50(5):1294\u20131301."},{"issue":"5","key":"b19","series-title":"Eur J Neurol","first-page":"1346","article-title":"Modifiable vascular risk factors in patients with cerebral and spinal cavernous malformations: a complete 10-year follow-up study","volume":"30","author":"Rauscher S","year":"2023","unstructured":"Rauscher S, Santos AN, Gull HH,  Modifiable vascular risk factors in patients with cerebral and spinal cavernous malformations: a complete 10-year follow-up study. Eur J Neurol. 2023;30(5):1346\u20131351."},{"issue":"1","key":"b20","series-title":"Pediatrics","first-page":"128","article-title":"Initiation and use of propranolol for infantile hemangioma: report of a consensus conference","volume":"131","author":"Drolet BA","year":"2013","unstructured":"Drolet BA, Frommelt PC, Chamlin SL,  Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131(1):128\u2013140."},{"issue":"5","key":"b21","series-title":"J Am Acad Dermatol","first-page":"833","article-title":"Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls","volume":"64","author":"Hermans DJJ","year":"2011","unstructured":"Hermans DJJ, van Beynum IM, Schultze Kool LJ, van de Kerkhof PCM, Wijnen MHWA, van der Vleuten CJM. Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls. J Am Acad Dermatol. 2011;64(5):833\u2013838."},{"issue":"4","key":"b22","series-title":"JAMA","first-page":"413","article-title":"Safety of propranolol therapy for severe infantile hemangioma","volume":"315","author":"Prey S","year":"2016","unstructured":"Prey S, Voisard JJ, Delarue A,  Safety of propranolol therapy for severe infantile hemangioma. JAMA. 2016;315(4):413\u2013415."},{"issue":"8","key":"b23","series-title":"N Engl J Med","first-page":"735","article-title":"A randomized, controlled trial of oral propranolol in infantile hemangioma","volume":"372","author":"L\u00e9aut\u00e9-Labr\u00e8ze C","year":"2015","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, Hoeger P, Mazereeuw-Hautier J,  A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372(8):735\u2013746."},{"key":"b24","series-title":"Placenta","first-page":"93","article-title":"The embryo-placental CD15-positive \"vasculogenic zones\" as a source of propranolol-sensitive pediatric vascular tumors","volume":"38","author":"Seidmann L","year":"2016","unstructured":"Seidmann L, Anspach L, Roth W. The embryo-placental CD15-positive \"vasculogenic zones\" as a source of propranolol-sensitive pediatric vascular tumors. Placenta. 2016;38:93\u201399."},{"issue":"1","key":"b25","series-title":"Lancet Neurol","first-page":"35","article-title":"Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial","volume":"22","author":"Lanfranconi S","year":"2023","unstructured":"Lanfranconi S, Scola E, Meessen JMTA,  Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial. Lancet Neurol. 2023;22(1):35\u201344."},{"issue":"3","key":"b26","series-title":"J Clin Invest","first-page":"e144893","article-title":"Propranolol inhibits cavernous vascular malformations by \u03b21 adrenergic receptor antagonism in animal models","volume":"131","author":"Li W","year":"2021","unstructured":"Li W, Shenkar R, Detter MR,  Propranolol inhibits cavernous vascular malformations by \u03b21 adrenergic receptor antagonism in animal models. J Clin Invest. 2021;131(3):e144893."},{"issue":"12","key":"b27","series-title":"Stroke","first-page":"3196","article-title":"Antithrombotic therapy and bleeding risk in a prospective cohort study of patients with cerebral cavernous malformations","volume":"43","author":"Schneble HM","year":"2012","unstructured":"Schneble HM, Soumare A, Herv\u00e9 D,  Antithrombotic therapy and bleeding risk in a prospective cohort study of patients with cerebral cavernous malformations. Stroke. 2012;43(12):3196\u20133199."},{"issue":"4","key":"b28","series-title":"Arterioscler Thromb Vasc Biol","first-page":"728","article-title":"Platelet adhesion receptors and their ligands in mouse models of thrombosis","volume":"27","author":"Denis CV","year":"2007","unstructured":"Denis CV, Wagner DD. Platelet adhesion receptors and their ligands in mouse models of thrombosis. Arterioscler Thromb Vasc Biol. 2007;27(4):728\u2013739."},{"issue":"4","key":"b29","series-title":"PLoS One","first-page":"e0122520","article-title":"The HAS-BLED score identifies patients with acute venous thromboembolism at high risk of major bleeding complications during the first six months of anticoagulant treatment","volume":"10","author":"Kooiman J","year":"2015","unstructured":"Kooiman J, van Hagen N, Iglesias Del Sol A,  The HAS-BLED score identifies patients with acute venous thromboembolism at high risk of major bleeding complications during the first six months of anticoagulant treatment. PLoS One. 2015;10(4):e0122520."},{"key":"b30","series-title":"Ann Vasc Surg","first-page":"190","article-title":"HAS-BLED score predicts the risk of major bleeding in chronic anticoagulation after lower limb surgical revascularization","volume":"59","author":"Freixo C","year":"2019","unstructured":"Freixo C, Ferreira V, Gon\u00e7alves J,  HAS-BLED score predicts the risk of major bleeding in chronic anticoagulation after lower limb surgical revascularization. Ann Vasc Surg. 2019;59:190\u2013194."},{"issue":"19","key":"b31","series-title":"J Am Heart Assoc","first-page":"e017316","article-title":"Predictors of bleeding in the perioperative anticoagulant use for surgery evaluation study","volume":"9","author":"Tafur AJ","year":"2020","unstructured":"Tafur AJ, Clark NP, Spyropoulos AC,  Predictors of bleeding in the perioperative anticoagulant use for surgery evaluation study. J Am Heart Assoc. 2020;9(19):e017316."},{"issue":"9","key":"b32","series-title":"J Am Coll Cardiol","first-page":"861","article-title":"Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study","volume":"60","author":"Apostolakis S","year":"2012","unstructured":"Apostolakis S, Lane DA, Guo Y, Buller H, Lip GYH. Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol. 2012;60(9):861\u2013867."},{"issue":"12","key":"b33","series-title":"Eur Heart J","first-page":"1500","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study","volume":"33","author":"Friberg L","year":"2012","unstructured":"Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500\u20131510."}],"container-title":["Neurosurgical Focus"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/neurosurg-focus\/55\/4\/article-pE15.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/neurosurg-focus\/55\/4\/article-pE15.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/neurosurg-focus\/55\/4\/article-pE15.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T08:24:03Z","timestamp":1779524643000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/neurosurg-focus\/55\/4\/article-pE15.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":66,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3171\/2023.7.focus23355","relation":{},"ISSN":["1092-0684"],"issn-type":[{"value":"1092-0684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]}}}